On July 13, the Department of Health and Human Services and the Department of Veterans Affairs signed a memorandum of understanding that could change how this country treats veteran PTSD for a generation. It’s a five-year agreement to coordinate research, train clinicians, and prepare the VA’s massive healthcare system to actually deliver rapid-acting psychedelic drug treatments — if and when the FDA approves them.
Read that again: if and when. This isn’t the VA handing out psilocybin tomorrow. It’s infrastructure-building — the VA is already running 20 active clinical trials in this space, backed by more than $23 million in outside research funding, and the new MOU is about making sure that when (or if) the FDA greenlights something, the system isn’t caught flat-footed. The FDA is moving in parallel, issuing formal guidance for how these clinical trials should be run and scheduling a public hearing on therapeutic use.
I’ll say plainly: I think this is worth taking seriously, and worth some cautious optimism. I’ve sat across from too many brothers who did multiple deployments and came home to a mental health system that offered them a pill and a pamphlet, sometimes not even that. Traditional SSRIs and years of talk therapy help some veterans enormously. They do not help everyone, and for a subset of guys carrying combat trauma that doesn’t respond to standard treatment, “rapid-acting” isn’t a marketing phrase — it’s the difference between getting help this year or not getting it at all.
But I want to be the guy in the room asking the uncomfortable question before this becomes a press release victory lap, because there’s a documented gap this initiative has to actually close, not just gesture at. VA’s own research has found that roughly 22 percent of deployed Black veterans report PTSD, compared to 14.1 percent of white veterans. That’s not a rounding error — that’s a meaningfully different burden of trauma carried by Black veterans specifically. And the reasons for that gap are well understood in the research: higher rates of combat exposure in certain roles historically, additional layers of racialized stress both in service and after, and a mental health care system that has never fully earned trust in Black communities, military or civilian.
So here’s my question for HHS and the VA as this MOU moves from paper to practice: who gets access first, and who gets left waiting? Clinical trials have a well-documented history of underrepresenting Black participants, sometimes because of genuine historical mistrust rooted in real abuses, sometimes because of who gets recruited and where the trial sites are located. If the next five years of research populate mostly with the veterans who already have the easiest relationship with VA facilities and the most flexibility to travel for treatment, we will end up with therapies validated on a population that doesn’t reflect who’s actually carrying the heaviest PTSD burden. That’s not a hypothetical risk. It’s the default outcome unless somebody in the room is fighting against it on purpose.
There’s also a stigma layer specific to Black veteran communities that this rollout needs to reckon with honestly. A therapy involving psychedelics is going to run headlong into a well-earned skepticism in Black communities about being first in line for experimental medicine — skepticism with historical receipts. The HHS-VA partnership will fail a lot of the veterans who need it most if it treats that skepticism as an outreach problem to be messaged around, rather than a trust problem to be earned through transparency: publishing who’s in the trials, publishing the safety data as it comes in, and putting Black clinicians and Black veteran service organizations at the table designing the rollout, not just receiving it after the fact.
None of this is an argument against the initiative. It’s an argument for watching it closely. My own path from combat deployment to civilian life taught me that the mental health system usually gets the big swings right in press releases and gets the details wrong in delivery — the actual appointment scheduling, the actual travel distance to a VA facility that runs the trial, the actual cultural competency of the therapist administering a treatment this intensive. Those details are where equity either happens or quietly doesn’t.
If you’re a veteran, particularly a Black veteran, following this story: don’t wait for a headline to tell you this is available. Ask your VA provider directly whether your facility, or the nearest research site, is participating in these trials, and ask what the eligibility criteria look like. Advocacy organizations tracking veteran mental health policy — locally, groups like the Center for Veterans Issues here in Milwaukee are worth watching for how they respond to this rollout regionally.
This could be one of the more significant veteran mental health developments in years. Whether it actually reaches the veterans carrying the heaviest weight is still an open question, and it’s one worth holding Washington to.